Status:

RECRUITING

Brown Fat as Therapeutic Strategy for Obesity and Associated Metabolic Diseases Via Functional Food/Nutraceutical Approach - Molecular Mechanisms of Pentacyclic Triterpenes (BRACE)

Lead Sponsor:

Institute for Human Development and Potential (IHDP), Singapore

Collaborating Sponsors:

National Medical Research Council (NMRC), Singapore

Conditions:

Diabetes

Brown Adipose Tissue

Eligibility:

All Genders

21-60 years

Phase:

NA

Brief Summary

To examine MA (Maslinic Acid) safety and efficacy in ameliorating insulin resistance and the cardinal features of metabolic syndrome. Chronic exposure to MA as a potent PPARgamma binder nutraceutical ...

Detailed Description

Up to 50 participants that are overweight/obese people suffering from metabolic syndrome/pre-metabolic syndrome will be recruited for this study. They will be asked to come to the Clinical Nutrition R...

Eligibility Criteria

Inclusion

  • Male or Female
  • Chinese ethnicity
  • Age between 21 to 60 years• Able to give informed consent
  • Body mass index (BMI) between 23 to 32 kg/m2
  • Thyroid function test must be within the normal ranges
  • Willing to avail yourself for the whole study and follow study procedures
  • EITHER deemed to have pre-metabolic syndrome when waist circumference is \> 90 cm in men or \> 80 cm in women, with none or up to one of the following condition:
  • Triglyceride level \>/= 1.7 mmol/L
  • HDL cholesterol \</= 1.0 mmol/L in men, and \</= 1.3 mmol/L in women
  • Blood pressure \>/= 130/85 mmHg
  • Fasting blood glucose \>/= 6.1 mmol/L
  • OR deemed to have metabolic syndrome when three or more of the following conditions are present:
  • Waist circumference \> 90 cm in men and \> 80 cm in women
  • Triglyceride level \>/= 1.7 mmol/L
  • HDL cholesterol\</= 1.0 mmol/L in men, and \</= 1.3 mmol/L in women
  • Blood pressure \>/= 130/85 mmHg
  • Fasting blood glucose \>/= 6.1 mmol/L

Exclusion

  • Are pregnant or contemplating pregnancy (for female subjects)
  • Partake in sports at the competitive and/ or endurance levels
  • Have known glucose-6-phosphate dehydrogenase (G6PD) deficiency
  • Have major chronic disease such as heart disease or cancer
  • Take insulin or drugs known to affect glucose metabolism
  • Intentionally restrict food intake
  • Have major medical or surgical event requiring hospitalization within the preceding 3 months
  • Have taken antibiotics for 3 months before the study period
  • Are a smoker
  • Are an overnight shift worker
  • Have any known food allergy (eg. anaphylaxis to peanuts) or skin allergy (eg. rashes due to alcohol, etc)
  • Having active Tuberculosis (TB) or currently receiving treatment for TB
  • Have any known Chronic Infection or known to suffer from or have previously suffered from or is a carrier of Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV)
  • Are a member of the research team or their immediate family members. Immediate family member is defined as a spouse, parent, child, or sibling, whether biological or legally adopted
  • Enrolled in a concurrent research study judged not to be scientifically or medically compatible with this study
  • Have poor veins impeding venous access
  • Have any history of severe vasovagal syncope (blackouts or near faints) following blood draws
  • History of claustrophobia

Key Trial Info

Start Date :

August 15 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

August 31 2027

Estimated Enrollment :

50 Patients enrolled

Trial Details

Trial ID

NCT06484543

Start Date

August 15 2024

End Date

August 31 2027

Last Update

October 15 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Singapore Institute of Clinical Sciences

Singapore, Singapore